The investigators propose conducting a randomized controlled trial at the Men's Health Clinic to evaluate whether patients who start and continue mirabegron postoperatively after undergoing Rezum therapy experience enhanced patient-reported outcomes, improved quality of life (QoL), and comparable rates of adverse events. There are no predicted adverse events of this study. There are no identified potential harms of this study.
age >50, symptomatic LUTS with IPSS ≥ 10
prostate volume 30-80cc on any imaging modality
Qmax between 5 and 15ml/s with minimum voided volume of 125cc
frequency ≥ 8 voids/day.
PVR greater than 300ml
active UTI within past week
previous surgical intervention for BPH
documented urethral stricture disease